<?xml version="1.0"?>
<!-- ArticleInstanceId : 3352855, Path: plosmed/9-2012/5/e1001218/preload/nxml/, Name : pmed.1001218.nxml -->
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article"
  dtd-version="3.0" xml:lang="en">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.0?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS Med</journal-id>
      <journal-id journal-id-type="publisher-id">PLoS</journal-id>
      <journal-id journal-id-type="pmc">plosmed</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">PLoS Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1549-1277</issn>
      <issn pub-type="epub">1549-1676</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">PMEDICINE-D-12-00386</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pmed.1001218</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Essay</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Drugs and Devices</subject>
            <subj-group>
              <subject>Drug Research and Development</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Global Health</subject>
          </subj-group>
          <subj-group>
            <subject>Public Health</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Science Policy</subject>
          <subj-group>
            <subject>Research Funding</subject>
          </subj-group>
          <subj-group>
            <subject>Science Policy and Economics</subject>
          </subj-group>
          <subj-group>
            <subject>Technology Development</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Social and Behavioral Sciences</subject>
          <subj-group>
            <subject>Law</subject>
          </subj-group>
          <subj-group>
            <subject>Political Science</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Innovation and Access to Medicines for Neglected Populations: Could a Treaty
          Address a Broken Pharmaceutical R&amp;D System?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Moon</surname>
            <given-names>Suerie</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Bermudez</surname>
            <given-names>Jorge</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>'t Hoen</surname>
            <given-names>Ellen</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Forum on Global Governance for Health, Harvard Global Health Institute,
          Cambridge, Massachusetts, United States of America</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Harvard School of Public Health, Boston, Massachusetts, United States of
          America</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>Funda&#xE7;&#xE3;o Oswaldo Cruz, Rio de Janeiro, Brazil</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>IS Academy HIV/AIDS, School for Social Science Research, University of Amsterdam,
          The Netherlands</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple"
          >smoon@hsph.harvard.edu</email></corresp>
        <fn fn-type="con">
          <p> manuscript: SM. Contributed to the writing of the manuscript: SM ETH JB. <ext-link
              ext-link-type="uri" xlink:href="http://www.icmje.org/" xlink:type="simple"
              >ICMJE</ext-link> criteria for authorship read and met: SM ETH JB. Agree with
            manuscript results and conclusions: SM ETH JB.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <month>5</month>
        <year>2012</year>
      </pub-date>
      <!-- Fake ppub added to accomodate plos workflow change from 03/2008 and 03/2009 -->
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>5</month>
        <year>2012</year>
      </pub-date>
      <volume>9</volume>
      <issue>5</issue>
      <elocation-id>e1001218</elocation-id>
      <permissions>
        <copyright-statement>Moon et al. This is an open-access article distributed under the terms
          of the Creative Commons Attribution License, which permits unrestricted use, distribution,
          and reproduction in any medium, provided the original author and source are
          credited.</copyright-statement>
        <copyright-year>2012</copyright-year>
      </permissions>
      <related-article xlink:href="info:doi/10.1371/journal.pmed.1001219"
        related-article-type="companion" ext-link-type="uri" id="d34e155" xlink:type="simple">
        <article-title>Scientific Standards and the Regulation of Genetically Modified
          Insects</article-title>
      </related-article>
      <abstract abstract-type="toc">
        <p>As part of a cluster of articles leading up to the 2012 World Health Report and
          critically reflecting on the theme of &#x201C;no health without research,&#x201D; Suerie
          Moon and colleagues argue for a global health R&amp;D treaty to improve innovation in new
          medicines and strengthening affordability, sustainable financing, efficiency in
          innovation, and equitable health-centered governance.</p>
      </abstract>
      <counts>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <boxed-text id="pmed-1001218-box001" position="float" orientation="portrait">
      <sec id="s1a">
        <title>Summary Points</title>
        <list list-type="bullet">
          <list-item>
            <p>The current system for the research and development (R&amp;D) of new medicines does
              not adequately meet the needs of the majority of the world's population.</p>
          </list-item>
          <list-item>
            <p>There is a lack of new medicines for the &#x201C;neglected
              diseases&#x201D;&#x2014;those that primarily affect populations with little purchasing
              power, and therefore offer an insufficient incentive for industry to invest in
              R&amp;D. However, with problems extending far beyond the narrow notion of neglected
              diseases, the issue is better understood as one of &#x201C;neglected
              populations.&#x201D;</p>
          </list-item>
          <list-item>
            <p>International debate and proposals for reform have ensued, including the
              recommendation that governments begin negotiations over a binding medical R&amp;D
              convention to address systematic, long-standing problems with innovation and globally
              equitable access to medicines. Despite the emergence of many new approaches to
              generating R&amp;D that meets the needs of poorer populations, efforts remain ad hoc,
              fragmented, and insufficient.</p>
          </list-item>
          <list-item>
            <p>We discuss how an R&amp;D treaty could complement and build on existing initiatives
              by addressing four areas where the system remains particularly weak: affordability,
              sustainable financing, efficiency in innovation, and equitable health-centered
              governance.</p>
          </list-item>
          <list-item>
            <p>We argue that effective tools for global governance are required to generate medical
              R&amp;D as a global public good, based on the understanding that a politically and
              financially sustainable system will require both fair contributions from all, and fair
              benefit-sharing for all.</p>
          </list-item>
        </list>
      </sec>
    </boxed-text>
    <disp-quote>
      <p>
        <italic>In anticipation of the 2012</italic> World Health Report, <italic>this paper was
          commissioned to help contextualize and critically reflect on the theme of &#x201C;no
          health without research.&#x201D;</italic>
      </p>
    </disp-quote>
    <sec id="s3">
      <title>Introduction</title>
      <p>Over the last two decades, recognition has grown that the current system for the research
        and development (R&amp;D) of new medicines does not adequately meet the needs of the
        majority of the world's population <xref ref-type="bibr" rid="pmed.1001218-The1"
          >[1]</xref>&#x2013;<xref ref-type="bibr" rid="pmed.1001218-World1">[4]</xref>, over 80% of
        which lives in low- and middle-income countries (LMICs) <xref ref-type="bibr"
          rid="pmed.1001218-The2">[5]</xref>. (We use the general term &#x201C;medicines&#x201D; to
        refer broadly to drugs, vaccines, diagnostics, and other medical products.)</p>
      <p>The clearest illustration of these shortcomings is the lack of new medicines for the
        &#x201C;neglected diseases&#x201D;&#x2014;those that primarily affect populations with
        little purchasing power, and therefore offer an insufficient incentive for industry to
        invest in R&amp;D. However, the problems with the existing system extend far beyond the
        narrow notion of neglected diseases. The challenge is better understood as one of
        &#x201C;neglected populations&#x201D;&#x2014;that is, of ensuring that the global R&amp;D
        system meets the needs of all, especially of the poorest and most vulnerable populations.
        Such needs include not only new treatments for neglected diseases, but also access to
        antimicrobials, affordable medicines for diseases with global incidence such as diabetes and
        cancer, and products well-adapted for use in resource-limited settings. Thus far, the
        existing system has largely failed to deliver on these objectives.</p>
      <p>These problems have prompted extensive international debate and proposals for reform. After
        a 2-year intergovernmental negotiation, in 2008 governments agreed upon the World Health
        Organization (WHO) Global Strategy and Plan of Action on Public Health, Innovation and
        Intellectual Property, which recognized that the current system fell short in meeting the
        needs of developing countries with respect to both communicable and non-communicable
        diseases <xref ref-type="bibr" rid="pmed.1001218-World1">[4]</xref>. In April 2012, the WHO
        Consultative Expert Working Group on R&amp;D: Financing and Coordination (CEWG) recommended
        that governments begin negotiations over a global medical R&amp;D convention to address some
        of these problems in a systematic way <xref ref-type="bibr" rid="pmed.1001218-WHO1"
          >[6]</xref> (see Box 1). Why might a binding international convention be needed?</p>
      <boxed-text id="pmed-1001218-box002" position="float" orientation="portrait">
        <sec id="s3a">
          <title>Box 1. A Binding WHO Convention on R&amp;D</title>
          <p>The idea of a binding international convention on R&amp;D has been debated since at
            least 2004, after an initial proposal by Hubbard and Love <xref ref-type="bibr"
              rid="pmed.1001218-Hubbard1">[55]</xref>,<xref ref-type="bibr"
              rid="pmed.1001218-DiMasi2">[60]</xref>. Over the years, it has received support from a
            number of governments, scientists, Nobel Laureates, civil society organizations, and
            other experts <xref ref-type="bibr" rid="pmed.1001218-Governments2"
              >[56]</xref>&#x2013;<xref ref-type="bibr" rid="pmed.1001218-Health1">[58]</xref>,<xref
              ref-type="bibr" rid="pmed.1001218-Fehr1">[61]</xref>&#x2013;<xref ref-type="bibr"
              rid="pmed.1001218-Velasquez1">[63]</xref>. Key features of treaty proposals include
            binding obligations on governments to invest in R&amp;D, equitable distribution of
            contributions across countries, priorities driven by health needs, measures to ensure
            affordability of the end product, and innovative approaches to incentivizing R&amp;D
              <xref ref-type="bibr" rid="pmed.1001218-Hubbard1">[55]</xref>,<xref ref-type="bibr"
              rid="pmed.1001218-Governments2">[56]</xref>,<xref ref-type="bibr"
              rid="pmed.1001218-Health1">[58]</xref>. Such a treaty could be crafted under the
            auspices of the WHO, whose Constitution allows for its 194 member states to negotiate
            formal international law (such as treaties, agreements, or conventions). Article 19 of
            the Constitution requires approval from two-thirds of member states to adopt any such
            agreement, and also allows individual member states to choose not to sign onto the
            agreement <xref ref-type="bibr" rid="pmed.1001218-World7">[64]</xref>. While both formal
            and informal norms (such as guidelines or global strategies) can influence the behavior
            of states and non-state actors, binding international law offers several potential
            advantages: it can provide for more predictable, reliable, and stable norms; carry
            stronger normative force, even in the absence of enforcement mechanisms; and can be more
            enforceable at national level <xref ref-type="bibr" rid="pmed.1001218-Hein1"
            >[65]</xref>. An important precedent was set with the 2005 Framework Convention on
            Tobacco Control, the first public health treaty negotiated within WHO, which has
            contributed significantly to global tobacco control efforts <xref ref-type="bibr"
              rid="pmed.1001218-Velasquez1">[63]</xref>,<xref ref-type="bibr"
              rid="pmed.1001218-Nikogosian1">[66]</xref>.</p>
        </sec>
      </boxed-text>
    </sec>
    <sec id="s4">
      <title>Shortcomings of the Current R&amp;D System</title>
      <p>Today, patents are the main policy tool to drive investments into medicines R&amp;D (Box 2)
        Prior to the 1990s, there was great variation among countries in the types and length of
        patents available&#x2014;on average, industrialized countries granted longer patent terms
        (15&#x2013;17 years), developing countries granted shorter terms (5&#x2013;10 years), and
        many countries&#x2014;including Western European nations&#x2014;made special exceptions for
        food, medicines, and agricultural technologies in their national patent laws <xref
          ref-type="bibr" rid="pmed.1001218-World2">[7]</xref>,<xref ref-type="bibr"
          rid="pmed.1001218-Watal1">[8]</xref>. However, since the 1995 entry into force of the
        World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property
        Rights (TRIPS), countries were required to harmonize their patent laws to the level of those
        developed in Western countries with large pharmaceutical industries. As a result, medicines
        are now subject to minimum 20-year patent terms in most WTO Members (except in
        least-developed country members, which have an extension until at least 2016 <xref
          ref-type="bibr" rid="pmed.1001218-World3">[9]</xref>).</p>
      <boxed-text id="pmed-1001218-box003" position="float" orientation="portrait">
        <sec id="s4a">
          <title>Box 2. The Current Global R&amp;D System</title>
          <p>Total public and private global investment in pharmaceutical R&amp;D was estimated at
            US$160 billion in 2005, of which about 97% came from high-income countries and 51% from
            the pharmaceutical industry <xref ref-type="bibr" rid="pmed.1001218-Burke1"
              >[50]</xref>,<xref ref-type="bibr" rid="pmed.1001218-Pharmaceutical1">[67]</xref>. In
            brief, the current R&amp;D system works as follows: governments invest in early-stage
            basic research, which is often carried out in public laboratories or academic
            institutions. The pharmaceutical industry then takes up promising leads and invests
            further in the development of a product, carrying out clinical trials to test if a
            medicine is safe and efficacious, then filing for regulatory approval. If successful,
            firms then market, sell, and distribute the medicine, usually under the protection
            provided by one or more patents and other regulatory measures; the higher prices enabled
            by these patents allow firms to recoup their R&amp;D investments and are paid by
            consumers or by public or private health insurance.</p>
        </sec>
      </boxed-text>
      <p>American economic historian Paul A. David has likened the patent system to a
        &#x201C;panda's thumb&#x201D;&#x2014;a product of centuries of evolution but poorly suited
        as a policy tool for modern innovation <xref ref-type="bibr" rid="pmed.1001218-David1"
          >[10]</xref>. Why was this system globalized?</p>
      <p>Medical knowledge has the potential to be a global public good&#x2014;that is, knowledge
        produced in one country can benefit the entire global community (it is
        &#x201C;non-excludable&#x201D;), and disclosing that knowledge does not reduce the amount of
        knowledge left for others to enjoy (it is &#x201C;non-rival&#x201D;) <xref ref-type="bibr"
          rid="pmed.1001218-Moon1">[11]</xref>. While there are potentially great social benefits
        from the public goods nature of medical knowledge, it also raises the question of how the
        burden of paying for such knowledge should be distributed globally. If one country can
        benefit from the investment of another, there is a powerful temptation to
        &#x201C;free-ride&#x201D; on the other's efforts; the end result may be aggregate global
        underinvestment in R&amp;D. One rationale for the global harmonization of patent policies
        was to distribute the burden of financing R&amp;D more uniformly across more countries, and
        to prevent free-riding <xref ref-type="bibr" rid="pmed.1001218-Drahos1">[12]</xref>,<xref
          ref-type="bibr" rid="pmed.1001218-Sell1">[13]</xref>.</p>
      <p>A key problem, however, was the application of uniform patent rules in a world with great
        wealth disparities: the average per capita income across all high-income countries
        (US$37,719) was 30 times that across all low- and lower-middle income countries (US$1,270)
          <xref ref-type="bibr" rid="pmed.1001218-The3">[14]</xref>. Yet, a patent allows a company
        to price a medicine at the same level in the United States as in India, as some firms have
        chosen to do <xref ref-type="bibr" rid="pmed.1001218-Strom1">[15]</xref>,<xref
          ref-type="bibr" rid="pmed.1001218-Kurian1">[16]</xref>. While a globalized patent system
        may be effective in dealing with the free rider problem, it does not equitably distribute
        the costs of R&amp;D and can block access to medicines for a large proportion of the
        population.</p>
      <p>Growing dissatisfaction with the existing system has raised the following question: could
        there be a more politically sustainable way to distribute R&amp;D costs across countries so
        that equitable access to medicines is not sacrificed?</p>
    </sec>
    <sec id="s5">
      <title>New Approaches to Access and Innovation</title>
      <p>Various policy experiments have been implemented or proposed to address both the access and
        innovation problems outlined above. HIV/AIDS provides the most significant example of
        improved access to widely patented medicines. Access to antiretroviral (ARV) medicines for
        HIV has increased over 14-fold since 2003, to reach 6.6 million people in 2010 <xref
          ref-type="bibr" rid="pmed.1001218-World4">[17]</xref>; such progress was enabled, in part,
        by low-cost generic ARVs made widely available through the use of TRIPS flexibilities by
        governments, the policies of patent holders, and the availability of international funding
        to support treatment programs <xref ref-type="bibr" rid="pmed.1001218-tHoen1"
        >[18]</xref>.</p>
      <p>In the area of innovation, there has been increased funding for specific neglected diseases
          <xref ref-type="bibr" rid="pmed.1001218-Moran1">[19]</xref>, technology transfer to build
        research and production capacity in developing countries <xref ref-type="bibr"
          rid="pmed.1001218-Butler1">[20]</xref>,<xref ref-type="bibr" rid="pmed.1001218-Moon2"
          >[21]</xref>, market creation to induce the development of pediatric formulations of ARVs
          <xref ref-type="bibr" rid="pmed.1001218-UNITAID1">[22]</xref>, an advanced market
        commitment to generate adapted pneumococcal vaccines <xref ref-type="bibr"
          rid="pmed.1001218-GAVI1">[23]</xref>, a priority regulatory review voucher granted in
        exchange for bringing a neglected disease drug to market <xref ref-type="bibr"
          rid="pmed.1001218-US1">[24]</xref>, the implementation of smaller milestone prizes and
        proposals for larger end-product prizes <xref ref-type="bibr" rid="pmed.1001218-Wilson1"
          >[25]</xref>&#x2013;<xref ref-type="bibr" rid="pmed.1001218-Travis1">[32]</xref>, upstream
        and downstream patent pools <xref ref-type="bibr" rid="pmed.1001218-Bermudez1"
          >[33]</xref>&#x2013;<xref ref-type="bibr" rid="pmed.1001218-World5">[35]</xref>, and
        open-source approaches <xref ref-type="bibr" rid="pmed.1001218-Open1"
          >[36]</xref>&#x2013;<xref ref-type="bibr" rid="pmed.1001218-Travis2">[38]</xref>.</p>
      <p>Of particular note are the product development partnerships (PDPs) dedicated to neglected
        disease R&amp;D, largely financed through public and philanthropic funds <xref
          ref-type="bibr" rid="pmed.1001218-Moran1">[19]</xref>,<xref ref-type="bibr"
          rid="pmed.1001218-Moran2">[39]</xref>,<xref ref-type="bibr" rid="pmed.1001218-Ziemba1"
          >[40]</xref>. Two examples of PDPs' potential to develop drugs at relatively low-cost are
        the Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV).
        From 2003 to 2011, with an investment of EUR100 million, DNDi built a pipeline of potential
        new drugs and developed six new products, including five combination treatments for malaria,
        sleeping sickness, and visceral leishmaniasis and a pediatric formulation for Chagas disease
          <xref ref-type="bibr" rid="pmed.1001218-Drugs1">[41]</xref>. Over a 10-year period with a
        budget of US$310 million, MMV developed three new products, including a pediatric
        formulation, injectable artesunate, and a new fixed-dose combination, and built a pipeline
        of nearly 60 projects <xref ref-type="bibr" rid="pmed.1001218-Medicines1">[42]</xref>. The
        costs of a non-profit PDP model that relies on contributions from and cooperation with both
        public and private partners cannot be compared directly to the pharmaceutical industry. Yet,
        the difference in scale between PDP and industry costs is striking, and underscores the need
        to give alternate models serious consideration. One estimate pegged the average
        private-sector cost to develop a new drug at US$1.3 billion <xref ref-type="bibr"
          rid="pmed.1001218-DiMasi1">[43]</xref>, though this figure has been contested and remains
        controversial <xref ref-type="bibr" rid="pmed.1001218-Goozner1">[44]</xref>,<xref
          ref-type="bibr" rid="pmed.1001218-Light1">[45]</xref>. Indeed, the pharmaceutical industry
        itself is testing new models for stimulating innovation, having recently hit a 25-year low
        in the number of new drugs coming to market <xref ref-type="bibr" rid="pmed.1001218-Munos1"
          >[37]</xref>,<xref ref-type="bibr" rid="pmed.1001218-Kaitin1">[46]</xref>.</p>
    </sec>
    <sec id="s6">
      <title>Rules of the System: Why We Need an R&amp;D Treaty</title>
      <p>The CEWG systematically assessed these various new approaches to improving the R&amp;D
        system and found particularly promising open-access approaches that &#x201C;de-link&#x201D;
        the financing of R&amp;D from the pricing of end products so that medicines can be sold near
        the cost of production. However, it also concluded that current efforts remain ad hoc,
        fragmented, and constrained by the tensions inherent in existing rules. Current initiatives
        lack a reliable, sustainable mechanism to generate sufficient funding for research, rely
        heavily on donor financing and priorities, and cover a limited set of diseases. Commenting
        on access to innovative medicines in developing countries, the head of Novartis succinctly
        said: &#x201C;We have no model which would meet the need for new drugs in a sustainable
        way&#x2026;. You can't expect for-profit organisations to do this in a large scale. If you
        want to establish a system where companies systematically invest in this kind of area you
        need a different system&#x201D; <xref ref-type="bibr" rid="pmed.1001218-Jack1"
        >[47]</xref>.</p>
      <p>An R&amp;D treaty could complement and build on existing initiatives by addressing four
        areas that remain particularly weak: affordability, sustainable financing, efficiency, and
        equitable governance.</p>
      <p>
        <bold>1. Affordability:</bold> Currently there is no system to ensure that new medicines
        will be affordable to the majority of people who need them. Despite major progress for HIV,
        no similar institutional arrangements exist for widely patented drugs in other therapeutic
        areas, such as the non-communicable diseases that account for nearly one-half of the burden
        of illness in LMICs <xref ref-type="bibr" rid="pmed.1001218-Fink1">[48]</xref>,<xref
          ref-type="bibr" rid="pmed.1001218-World6">[49]</xref>. Affordability is likely to be an
        even bigger problem for biologics, for which generic competition is more limited than for
        traditional small-molecule drugs. A treaty could include measures to ensure affordability,
        including new incentive mechanisms that incorporate the principle of de-linkage. Examples
        include licensing through the Medicines Patent Pool or using treaty-generated funds to
        reward a prize to a successful drug developer, both of which allow for competitive generic
        production of the drug <xref ref-type="bibr" rid="pmed.1001218-Love1">[27]</xref>. Such
        approaches could engender more equitable access to the benefits of scientific progress, but
        would also require reliable financial contributions across countries. Establishing the
        ground rules for such a system is likely to require a binding legal instrument. </p>
      <p>
        <bold>2. Sustainable Financing:</bold> Currently there are no mechanisms to ensure
        sufficient, predictable financing of R&amp;D to meet health needs in LMICs. Donor
        governments and non-profit entities, such as the Gates Foundation, have invested
        significantly in neglected disease R&amp;D, with total global funding estimated at US$3
        billion in 2010, and resulting in 140 products in development from a baseline of almost zero
        a decade ago <xref ref-type="bibr" rid="pmed.1001218-Moran1">[19]</xref>. While such
        progress is laudable, neglected disease R&amp;D funding remains a small proportion of global
        spending (about 2%). And these figures cover only neglected diseases, not the broader range
        of R&amp;D needs of neglected populations. However, at the same time that needs are
        increasing, for example as PDPs move promising compounds into clinical trials, neglected
        disease R&amp;D funding has declined in the past year due to decreased donor contributions
        amidst the economic crisis <xref ref-type="bibr" rid="pmed.1001218-Moran1">[19]</xref>. This
        decline highlights the need for more sustainable financing arrangements, including the
        potential use of innovative financing mechanisms that tap into the growing capacity of
        middle-income countries to contribute to R&amp;D. LMICs contributed an estimated US$5
        billion to health R&amp;D in 2005 <xref ref-type="bibr" rid="pmed.1001218-Burke1"
          >[50]</xref>. </p>
      <p>A treaty could include binding obligations on governments to contribute to R&amp;D, with
        due regard for varying ability to pay, thereby addressing the free-rider problem while
        establishing equitable burden-sharing arrangements. An international agreement is likely to
        be required to establish robust, sustainable, predictable, and sufficient financial flows
        for R&amp;D.</p>
      <p>
        <bold>3. Efficiency in Innovation:</bold> There is considerable room for improving the
        efficiency of the innovation process. For example, by impeding the free flow of information,
        intellectual property rights can retard the accumulation of common knowledge that drives
        forward scientific progress <xref ref-type="bibr" rid="pmed.1001218-Heller1"
          >[51]</xref>,<xref ref-type="bibr" rid="pmed.1001218-Jaffe1">[52]</xref>. Recognizing this
        problem, open-source R&amp;D initiatives by publicly funded research labs or pre-competitive
        platforms among pharmaceutical firms have been established to facilitate knowledge-sharing;
        these initiatives hold promise, but remain few and nascent <xref ref-type="bibr"
          rid="pmed.1001218-Massum1">[53]</xref>. Another inefficiency arises from market incentives
        that reward the development of &#x201C;me-too&#x201D; drugs that are lucrative, but similar
        to pre-existing medicines and/or offer little or no therapeutic advance <xref
          ref-type="bibr" rid="pmed.1001218-Angell1">[54]</xref>. However, we have no global ground
        rules to facilitate open-source approaches, nor to counteract duplicative R&amp;D
        investments in some areas or the relative neglect of others. A treaty could establish rules
        to improve efficiency in innovation. For example, global norms regarding research priorities
        and transparency in investment decisions could facilitate more efficient self-organization
        of the global scientific community. A treaty would not necessarily imply a centralized body
        directing all research activities, but rather, could establish rules that foster creativity
        such as incentives for faster global knowledge-sharing. </p>
      <p>
        <bold>4. Equitable Health-Focused Governance:</bold> Market incentives, not health needs or
        public priorities, largely drive private R&amp;D investments. A treaty could craft
        governance arrangements to ensure that the public interest drives innovation, rather than
        market-generated profits alone. For example, treaty rules could structure financial rewards
        for innovation so that they are commensurate with a medicine's health benefit <xref
          ref-type="bibr" rid="pmed.1001218-Banerjee1">[31]</xref>. In addition, as noted above,
        donors play a central role in financing the R&amp;D now dedicated to the specific needs of
        developing countries&#x2014;a welcome contribution, but one that also leaves
        priority-setting decisions largely in their hands. A system in which all countries
        contributed finances and knowledge could form the basis of more equitable governance
        arrangements in which affected populations have a stronger voice in decision-making. </p>
      <p>Treaty proposals have included other measures, such as those to encourage regional
        cooperation among regulatory authorities, or enhance transparency in clinical trial results
          <xref ref-type="bibr" rid="pmed.1001218-Hubbard1">[55]</xref>&#x2013;<xref ref-type="bibr"
          rid="pmed.1001218-Health1">[58]</xref>. But since a comparative review of the proposals
        lies beyond the scope of this article, we have highlighted the four main systemic weaknesses
        above as forming the core rationale for a binding international instrument.</p>
      <p>Some of these weaknesses can be addressed, at least in part, through national action. For
        example, patents can be licensed to improve affordability, and pharmacoeconomic assessments
        for medicines can link reimbursements to therapeutic efficacy. However, in a world in which
        information flows instantly across borders, research is carried out in dispersed networks,
        trade in medicines spans the globe, and intellectual property rules have already been
        globalized, coherent systemic change requires the negotiation of global rules. This, in
        turn, requires the collective engagement of governments.</p>
      <p>The mere negotiation of a treaty will not be a panacea, and several areas require
        particular vigilance. First, as with most areas of international law, enforcement remains a
        thorny issue. Treaty negotiators will need to pay special attention to mechanisms that
        encourage compliance and manage free-riding. Such mechanisms could include traditional
        methods such as reporting and transparency requirements, as well as tools that have more
        teeth, such as provisions allowing countries that contribute <italic>ex ante</italic> to
        R&amp;D through the treaty to pay lower prices for the medicines that are developed, while
        non-participating countries pay more. Second, treaty negotiations should not be seen as a
        replacement for ongoing policy experiments in new ways to generate innovation; such efforts
        should continue both for the immediate health benefits they can deliver through new
        products, and for the evidence they can provide to inform longer-term treaty design.
        Finally, treaty negotiations promise to be complex, lengthy, and resource-intensive. In
        order to merit such costly efforts, the final treaty must meet at least four key objectives:
        affordability of medicines, sustainable R&amp;D finance, freer sharing of knowledge, and
        equitable governance that puts health at the system's core.</p>
    </sec>
    <sec sec-type="conclusions" id="s7">
      <title>Conclusions</title>
      <p>Medical innovation and access to the fruits of scientific progress are no longer policy
        concerns restricted to the national level or to wealthy countries alone. In an era of health
        interdependence, effective tools for global governance are required to generate medical
        R&amp;D as a global public good that can deliver benefits for all <xref ref-type="bibr"
          rid="pmed.1001218-Moon1">[11]</xref>,<xref ref-type="bibr" rid="pmed.1001218-Chen1"
          >[59]</xref>. A treaty is a promising tool for improving the coherence, fairness,
        efficiency, and sustainability of the global R&amp;D system. It should be based on the
        understanding that a politically and financially sustainable system for generating health
        research will require both fair contributions from all, and fair benefit-sharing for
        all.</p>
      <p>The recommendations of the CEWG can be seen as the product of nearly two decades of growing
        dissatisfaction with the shortcomings of the current R&amp;D system. Leaders of governments,
        civil society, industry, and academia should seize this unprecedented opportunity to move
        forward.</p>
    </sec>
    <sec sec-type="supplementary-material" id="s8">
      <title>Supporting Information</title>
      <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" content-type="local-data"
        id="pmed.1001218.s001" position="float" orientation="portrait" xlink:type="simple">
        <label>Alternative Language Abstract S1 Translation of the Summary Points into Dutch</label>
        <caption>
          <p>(DOCX)</p>
        </caption>
        <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pmed.1001218.s001.docx"
          mimetype="application" mime-subtype="msword" position="float" orientation="portrait"
          xlink:type="simple">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" content-type="local-data"
        id="pmed.1001218.s002" position="float" orientation="portrait" xlink:type="simple">
        <label>Alternative Language Abstract S2 Translation of the Summary Points into French and
          Spanish</label>
        <caption>
          <p>(DOC)</p>
        </caption>
        <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pmed.1001218.s002.doc"
          mimetype="application" mime-subtype="msword" position="float" orientation="portrait"
          xlink:type="simple">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" content-type="local-data"
        id="pmed.1001218.s003" position="float" orientation="portrait" xlink:type="simple">
        <label>Alternative Language Abstract S3 Translation of the Summary Points into
          Portuguese</label>
        <caption>
          <p>(DOCX)</p>
        </caption>
        <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pmed.1001218.s003.docx"
          mimetype="application" mime-subtype="msword" position="float" orientation="portrait"
          xlink:type="simple">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>SM is a member of the Board of Directors of Medecins Sans Frontieres (MSF)/Doctors
          Without Borders-USA and the Drugs for Neglected Diseases initiative-North America. ETH was
          the executive director of the Medicines Patent Pool from November 2010 until 1 May 2012.
          SM has been a consultant to the Medicines Patent Pool. All other authors have declared
          that no competing interests exist.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>No specific funding was received for writing this article.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Provenance:</bold> Commissioned; externally peer reviewed. </p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="pmed.1001218-The1">
        <label>1</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">The Commission on Health Research for Development</collab>
          <year>1990</year>
          <article-title>Health research: Essential link to equity in development.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.cohred.org/downloads/open_archive/ComReports_0.pdf"
              xlink:type="simple"
              >http://www.cohred.org/downloads/open_archive/ComReports_0.pdf</ext-link>. Accessed 11
            April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-United1">
        <label>2</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">United Kingdom Commission on Intellectual Property Rights
            (CIPR)</collab>
          <year>2002</year>
          <article-title>Integrating intellectual property rights and development
            policy.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.iprcommission.org/graphic/documents/final_report.htm"
              xlink:type="simple"
              >http://www.iprcommission.org/graphic/documents/final_report.htm</ext-link>. Accessed
            11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Commission1">
        <label>3</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Commission on Intellectual Property Rights, Innovation and
            Public Health (CIPIH)</collab>
          <year>2006</year>
          <article-title>Public health, innovation and intellectual property rights.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/intellectualproperty/report/en/index.html"
              xlink:type="simple"
              >http://www.who.int/intellectualproperty/report/en/index.html</ext-link>. Accessed 11
            April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-World1">
        <label>4</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Assembly (WHA)</collab>
          <year>2008</year>
          <article-title>Global strategy and plan of action on public health, innovation and
            intellectual property.</article-title>
          <comment>Resolution 61.21(Sixty-first). Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf"
              xlink:type="simple"
              >http://www.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf</ext-link>. Accessed 11
            April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-The2">
        <label>5</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">The World Bank</collab>
          <year>2012</year>
          <article-title>The World Bank&#x2013;data.</article-title>
          <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://data.worldbank.org/"
              xlink:type="simple">http://data.worldbank.org/</ext-link>. Accessed 5 February
            2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-WHO1">
        <label>6</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">WHO Consultative Expert Working Group on Research and
            Development (CEWG): Financing and Coordination</collab>
          <year>2012</year>
          <article-title>Research and development to meet health needs in developing countries:
            Strengthening global financing and coordination.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/phi/CEWG_Report_5_April_2012.pdf" xlink:type="simple"
              >http://www.who.int/phi/CEWG_Report_5_April_2012.pdf</ext-link>. Accessed 11 April
            2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-World2">
        <label>7</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Intellectual Property Organization (WIPO)</collab>
          <year>1988</year>
          <article-title>Existence, scope and form of generally internationally accepted and applied
            Standards/Norms for the protection of intellectual property - note prepared by the
            international bureau of WIPO-revision.</article-title>
          <comment>MTN.GNG/NG11/W/24/Rev.1</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Watal1">
        <label>8</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Watal</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <year>2001</year>
          <source>Intellectual property rights in the WTO and developing countries</source>
          <publisher-loc>The Hague</publisher-loc>
          <publisher-name>Kluwer Law International</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-World3">
        <label>9</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Trade Organization (WTO)</collab>
          <year>2001</year>
          <article-title>Declaration on the TRIPS agreement and public health.</article-title>
          <comment>WT/MIN(01)/DEC/2</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-David1">
        <label>10</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>David</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <year>1993</year>
          <article-title>Intellectual property institutions and the panda's thumb: Patents,
            copyrights, and trade secrets in economic theory and history.</article-title>
          <person-group person-group-type="editor">
            <name name-style="western">
              <surname>Wallerstein</surname>
              <given-names>MB</given-names>
            </name>
            <name name-style="western">
              <surname>Mogee</surname>
              <given-names>ME</given-names>
            </name>
            <name name-style="western">
              <surname>Schoen</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <source>Global dimensions of intellectual property rights in science and
            technology</source>
          <publisher-loc>Washington (D.C.)</publisher-loc>
          <publisher-name>The National Academies Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Moon1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Moon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <year>2009</year>
          <article-title>Medicines as global public goods: The governance of technological
            innovation in the new era of global health.</article-title>
          <source>Global Health Governance</source>
          <volume>2</volume>
          <issue>2</issue>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Drahos1">
        <label>12</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Drahos</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Braithwaite</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <year>2002</year>
          <source>Information feudalism: Who owns the knowledge economy?</source>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>The New Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Sell1">
        <label>13</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sell</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <year>2003</year>
          <source>Private power, public law: The globalization of intellectual property
            rights</source>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Cambridge University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-The3">
        <label>14</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">The World Bank</collab>
          <year>2012</year>
          <article-title>Data: GNI per capita, Atlas method (current US$).</article-title>
          <comment>Accessed 1 February 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Strom1">
        <label>15</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Strom</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Fleischer-Black</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <year>2003</year>
          <article-title>Drug maker's vow to donate cancer drug falls short.</article-title>
          <comment>The New York Times. Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.nytimes.com/2003/06/05/business/05DRUG.html"
              xlink:type="simple">http://www.nytimes.com/2003/06/05/business/05DRUG.html</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Kurian1">
        <label>16</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kurian</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <year>2012</year>
          <article-title>In the matter of Natco Pharma Limited and Bayer
            Corporation.</article-title>
          <comment>Compulsory License Application No. 1 of 2011. Available: <ext-link
              ext-link-type="uri"
              xlink:href="http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf"
              xlink:type="simple"
              >http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf</ext-link>. Accessed
            11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-World4">
        <label>17</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Organization, Joint United Nations Programme on
            HIV/AIDS (UNAIDS), United Nations Children's Fund</collab>
          <year>2011</year>
          <article-title>Progress report 2011: Global HIV/AIDS response.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/hiv/pub/progress_report2011/en/index.html"
              xlink:type="simple"
              >http://www.who.int/hiv/pub/progress_report2011/en/index.html</ext-link>. Accessed 11
            April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-tHoen1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>'t Hoen</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Berger</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Calmy</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Moon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>Driving a decade of change: HIV/AIDS, patents, and access to
            medicines.</article-title>
          <source>J Int AIDS Soc</source>
          <volume>14</volume>
          <fpage>15</fpage>
          <pub-id pub-id-type="pmid">21439089</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Moran1">
        <label>19</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Moran</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Guzman</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Abela-Oversteegen</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Liyanage</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Omune</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <year>2011</year>
          <article-title>G-FINDER report 2011: Neglected disease research and development: Is
            innovation under threat?</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.policycures.org/downloads/g-finder_2011.pdf"
              xlink:type="simple">http://www.policycures.org/downloads/g-finder_2011.pdf</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Butler1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Butler</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <year>2010</year>
          <article-title>Vaccine offers meningitis hope.</article-title>
          <source>Nature</source>
          <volume>468</volume>
          <fpage>143</fpage>
          <pub-id pub-id-type="pmid">21068797</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Moon2">
        <label>21</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Moon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <source>Pharmaceutical production and related technology transfer</source>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization (WHO)</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-UNITAID1">
        <label>22</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">UNITAID</collab>
          <year>2011</year>
          <article-title>UNITAID annual report 2010.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.unitaid.eu/images/NewWeb/documents/AR10/unitaid_ar2010_web.pdf"
              xlink:type="simple"
              >http://www.unitaid.eu/images/NewWeb/documents/AR10/unitaid_ar2010_web.pdf</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-GAVI1">
        <label>23</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">GAVI Alliance Secretariat</collab>
          <year>2010</year>
          <comment>Advance market commitment for pneumococcal vaccines: Annual report 12 June
            2009&#x2013;31 March 2010</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-US1">
        <label>24</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">US Food and Drug Administration</collab>
          <year>2008</year>
          <article-title>Guidance for industry: Tropical disease priority review
            vouchers.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0530-gdl.pdf"
              xlink:type="simple"
              >http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0530-gdl.pdf</ext-link>. Accessed 11
            April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Wilson1">
        <label>25</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Wilson</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Palriwala</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>Prizes for global health technologies.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.resultsfordevelopment.org/sites/resultsfordevelopment.org/files/resources/R4D-PrizesReport.pdf"
              xlink:type="simple"
              >http://www.resultsfordevelopment.org/sites/resultsfordevelopment.org/files/resources/R4D-PrizesReport.pdf</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Crager1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Crager</surname>
              <given-names>SE</given-names>
            </name>
            <name name-style="western">
              <surname>Price</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <year>2009</year>
          <article-title>Prizes and parasites: Incentive models for addressing Chagas
            disease.</article-title>
          <source>J Law Med Ethics</source>
          <volume>37</volume>
          <issue>2</issue>
          <fpage>292</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="pmid">19493074</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Love1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Love</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Hubbard</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <year>2009</year>
          <article-title>Prizes for innovation of new medicines and vaccines.</article-title>
          <source>Annals of Health Law</source>
          <volume>18</volume>
          <fpage>155</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="pmid">21950238</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Governments1">
        <label>28</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Governments of Bangladesh, Barbados, Bolivia and
            Suriname</collab>
          <year>2009</year>
          <article-title>Chagas disease prize fund for the development of new treatments,
            diagnostics and vaccines.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_ChagasPrize.pdf"
              xlink:type="simple"
              >http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_ChagasPrize.pdf</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Wei1">
        <label>29</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Wei</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <year>2007</year>
          <article-title>Should prizes replace patents?</article-title>
          <comment>A critique of the Medical Innovation Prize Act of 2005. Boston University Journal
            of Science and Technology Law (Working Paper)</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Finkelstein1">
        <label>30</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Finkelstein</surname>
              <given-names>SN</given-names>
            </name>
            <name name-style="western">
              <surname>Temin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <year>2008</year>
          <source>Reasonable Rx: Solving the drug price crisis</source>
          <publisher-loc>Upper Saddle River, N.J.</publisher-loc>
          <publisher-name>FT Press/Pearson Education</publisher-name>
          <size units="page">188</size>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Banerjee1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Banerjee</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Hollis</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Pogge</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <year>2010</year>
          <article-title>The health impact fund: Incentives for improving access to
            medicines.</article-title>
          <source>Lancet</source>
          <volume>375</volume>
          <issue>9709</issue>
          <fpage>166</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="pmid">20109894</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Travis1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Travis</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <year>2008</year>
          <article-title>Research funding. Prizes eyed to spur medical innovation.</article-title>
          <source>Science</source>
          <volume>319</volume>
          <issue>5864</issue>
          <fpage>713</fpage>
          <pub-id pub-id-type="pmid">18258868</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Bermudez1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Bermudez</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>'t Hoen</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <year>2010</year>
          <article-title>The UNITAID patent pool initiative: Bringing patents together for the
            common good.</article-title>
          <source>Open AIDS J</source>
          <volume>4</volume>
          <fpage>37</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">20309404</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Serafino1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Serafino</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <year>2007</year>
          <article-title>Survey of patent pools demonstrates variety of purposes and management
            structures.</article-title>
          <source>KEI Research Note</source>
          <volume>6</volume>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-World5">
        <label>35</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Intellectual Property Organization</collab>
          <year>2011</year>
          <article-title>WIPO re:Search. Retrieved 5 February 20120.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.wipo.int/research/en/" xlink:type="simple"
              >http://www.wipo.int/research/en/</ext-link>. Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Open1">
        <label>36</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Open Source Drug Discovery</collab>
          <year>2012</year>
          <article-title>Open source drug discovery.</article-title>
          <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.osdd.net/home"
              xlink:type="simple">http://www.osdd.net/home</ext-link>. Accessed 11 April
            2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Munos1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Munos</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <year>2010</year>
          <article-title>Can open source drug R&amp;D repower pharmaceutical
            innovation?</article-title>
          <source>Clin Pharmacol Ther</source>
          <volume>87</volume>
          <fpage>534</fpage>
          <lpage>536</lpage>
          <pub-id pub-id-type="pmid">20407458</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Travis2">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Travis</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <year>2008</year>
          <article-title>Science and commerce. Science by the masses.</article-title>
          <source>Science</source>
          <volume>319</volume>
          <issue>5871</issue>
          <fpage>1750</fpage>
          <lpage>1752</lpage>
          <pub-id pub-id-type="pmid">18369115</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Moran2">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Moran</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <year>2005</year>
          <article-title>A breakthrough in R&amp;D for neglected diseases: New ways to get the drugs
            we need.</article-title>
          <source>PLoS Med</source>
          <volume>2</volume>
          <issue>9</issue>
          <fpage>e302</fpage>
          <comment>doi:<ext-link ext-link-type="uri"
              xlink:href="http://dx.doi.org/10.1371/journal.pmed.0020302" xlink:type="simple"
              >10.1371/journal.pmed.0020302</ext-link></comment>
          <pub-id pub-id-type="pmid">16138789</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Ziemba1">
        <label>40</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ziemba</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <year>2005</year>
          <article-title>Public-private partnerships for product development: Financial, scientific,
            and managerial issues as challenges to future success.</article-title>
          <comment>Research report for the WHO Commission on Intellectual Property Rights,
            Innovation, and Public Health</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Drugs1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <collab xlink:type="simple">Drugs for Neglected Diseases initiative (DNDi)</collab>
          <year>2011</year>
          <article-title>Financing &amp; incentives for neglected disease R&amp;D: Opportunities and
            challenges: Comments to the WHO consultative expert working group (CEWG) on research
            &amp; development: Financing and coordination &#x2013; June 2011.</article-title>
          <source>DNDi Outlook</source>
          <issue>3</issue>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Medicines1">
        <label>42</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Medicines for Malaria Venture</collab>
          <year>2012</year>
          <article-title>How cost effective is MMV?</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.mmv.org/about-us/faqs/how-cost-effective-mmv"
              xlink:type="simple"
            >http://www.mmv.org/about-us/faqs/how-cost-effective-mmv</ext-link>. Accessed 11 April
            2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-DiMasi1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>DiMasi</surname>
              <given-names>JA</given-names>
            </name>
            <name name-style="western">
              <surname>Grabowski</surname>
              <given-names>HG</given-names>
            </name>
          </person-group>
          <year>2007</year>
          <article-title>The cost of biopharmaceutical R&amp;D: Is biotech
            different?</article-title>
          <source>Managerial and Decision Economics</source>
          <volume>28</volume>
          <issue>4&#x2013;5</issue>
          <fpage>469</fpage>
          <lpage>479</lpage>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Goozner1">
        <label>44</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Goozner</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <year>2004</year>
          <source>The $800 million pill: The truth behind the cost of new drugs</source>
          <publisher-loc>Berkeley</publisher-loc>
          <publisher-name>University of California Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Light1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Light</surname>
              <given-names>DW</given-names>
            </name>
            <name name-style="western">
              <surname>Warburton</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>Demythologizing the high costs of pharmaceutical research.</article-title>
          <source>BioSocieties</source>
          <fpage>1</fpage>
          <lpage>17</lpage>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Kaitin1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kaitin</surname>
              <given-names>KI</given-names>
            </name>
            <name name-style="western">
              <surname>DiMasi</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>Pharmaceutical innovation in the 21st century: New drug approvals in the
            first decade, 2000&#x2013;2009.</article-title>
          <source>Clin Pharmacol Ther</source>
          <volume>89</volume>
          <issue>2</issue>
          <fpage>183</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="pmid">21191382</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Jack1">
        <label>47</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Jack</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <year>2006</year>
          <article-title>Novartis chief in warning on cheap drugs.</article-title>
          <comment>The Financial Times. Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.ft.com/intl/cms/s/0/6cfd37e8-5020-11db-9d85-0000779e2340.html"
              xlink:type="simple"
              >http://www.ft.com/intl/cms/s/0/6cfd37e8-5020-11db-9d85-0000779e2340.html</ext-link>.
            [Requires free registration]. Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Fink1">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Fink</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Rabinowitz</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>The UN's battle with NCDs: How politics, commerce, and science complicated
            the fight against an &#x201C;invisible epidemic&#x201D;.</article-title>
          <source>Foreign Affairs (September)</source>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-World6">
        <label>49</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Organization</collab>
          <year>2008</year>
          <article-title>The global burden of disease: 2004 update.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html"
              xlink:type="simple"
              >http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Burke1">
        <label>50</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="editor">
            <name name-style="western">
              <surname>Burke</surname>
              <given-names>MA</given-names>
            </name>
            <name name-style="western">
              <surname>Matlin</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <year>2008</year>
          <source>Global forum for health research, monitoring financial flows for health research
            2008</source>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>Global Forum for Health Research</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Heller1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Heller</surname>
              <given-names>MA</given-names>
            </name>
            <name name-style="western">
              <surname>Eisenberg</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <year>1998</year>
          <article-title>Can patents deter innovation? The anticommons in biomedical
            research.</article-title>
          <source>Science</source>
          <volume>280</volume>
          <issue>5364</issue>
          <fpage>698</fpage>
          <lpage>701</lpage>
          <pub-id pub-id-type="pmid">9563938</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Jaffe1">
        <label>52</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Jaffe</surname>
              <given-names>AB</given-names>
            </name>
            <name name-style="western">
              <surname>Lerner</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <year>2004</year>
          <source>Innovation and its discontents: How our broken patent system is endangering
            innovation and progress, and what to do about it</source>
          <publisher-loc>Princeton, N.J.</publisher-loc>
          <publisher-name>Princeton University Press</publisher-name>
          <size units="page">236</size>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Massum1">
        <label>53</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Massum</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Harris</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>Open source for neglected diseases: Magic bullet or mirage?</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.resultsfordevelopment.org/sites/resultsfordevelopment.org/files/Open%20Source%20for%20Neglected%20Diseases.pdf"
              xlink:type="simple"
              >http://www.resultsfordevelopment.org/sites/resultsfordevelopment.org/files/Open%20Source%20for%20Neglected%20Diseases.pdf</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Angell1">
        <label>54</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Angell</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <year>2004</year>
          <source>The truth about the drug companies: How they deceive us and what to do about
            it</source>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Random House</publisher-name>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Hubbard1">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hubbard</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Love</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <year>2004</year>
          <article-title>A new trade framework for global healthcare R&amp;D.</article-title>
          <source>PLoS Biol</source>
          <volume>2</volume>
          <issue>2</issue>
          <fpage>e52</fpage>
          <comment>doi:<ext-link ext-link-type="uri"
              xlink:href="http://dx.doi.org/10.1371/journal.pbio.0020052" xlink:type="simple"
              >10.1371/journal.pbio.0020052</ext-link></comment>
          <pub-id pub-id-type="pmid">14966544</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Governments2">
        <label>56</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Governments of Bangladesh, Barbados, Bolivia, and
            Suriname</collab>
          <year>2009</year>
          <article-title>Proposal for WHO discussions on a biomedical R&amp;D
            treaty.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_R_DTreaty.pdf"
              xlink:type="simple"
              >http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_R_DTreaty.pdf</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Dentico1">
        <label>57</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dentico</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Ford</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <year>2005</year>
          <article-title>The courage to change the rules: A proposal for an essential health R&amp;D
            treaty.</article-title>
          <source>PLoS Med</source>
          <volume>2</volume>
          <issue>2</issue>
          <fpage>e14</fpage>
          <comment>doi:<ext-link ext-link-type="uri"
              xlink:href="http://dx.doi.org/10.1371/journal.pmed.0020014" xlink:type="simple"
              >10.1371/journal.pmed.0020014</ext-link></comment>
          <pub-id pub-id-type="pmid">15736991</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Health1">
        <label>58</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Health Action International Global, Initiative for Health and
            Equity in Society, Knowledge Ecology International, Medecins Sans Frontieres, Third
            World Network</collab>
          <year>2011</year>
          <article-title>An essential health &amp; biomedical treaty.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/phi/news/phi_1_joint_submission_en.pdf"
              xlink:type="simple"
              >http://www.who.int/phi/news/phi_1_joint_submission_en.pdf</ext-link>. Accessed 11
            April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Chen1">
        <label>59</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Chen</surname>
              <given-names>LC</given-names>
            </name>
            <name name-style="western">
              <surname>Evans</surname>
              <given-names>TG</given-names>
            </name>
            <name name-style="western">
              <surname>Cash</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <year>1999</year>
          <article-title>Health as a global public good.</article-title>
          <person-group person-group-type="editor">
            <name name-style="western">
              <surname>Kaul</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Grunberg</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Stern</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <source>Global Public Goods: International Cooperation in the 21st Century</source>
          <publisher-loc>Oxford and New York</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
          <fpage>284</fpage>
          <lpage>304</lpage>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-DiMasi2">
        <label>60</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>DiMasi</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Grabowski</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <year>2004</year>
          <article-title>Patents and R&amp;D incentives: Comments on the Hubbard and Love trade
            framework for financing pharmaceutical R&amp;D.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/intellectualproperty/news/en/Submission3.pdf"
              xlink:type="simple"
              >http://www.who.int/intellectualproperty/news/en/Submission3.pdf</ext-link>. Accessed
            11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Fehr1">
        <label>61</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Fehr</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Thurmann</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Razum</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>Expert Delphi survey on research and development into drugs for neglected
            diseases.</article-title>
          <source>BMC Health Services Research</source>
          <volume>11</volume>
          <issue>1</issue>
          <fpage>312</fpage>
          <pub-id pub-id-type="pmid">22087801</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Love2">
        <label>62</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Love</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Hubbard</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Khor</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Sulston</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Stoppa-Lyonet</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <year>2005</year>
          <article-title>Letter to WHA executive board: Request to evaluate proposal for new global
            medical R&amp;D treaty.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/intellectualproperty/submissions/CPTech.pdf"
              xlink:type="simple"
              >http://www.who.int/intellectualproperty/submissions/CPTech.pdf</ext-link>. Accessed
            11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Velasquez1">
        <label>63</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Velasquez</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Seuba</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <year>2011</year>
          <article-title>Rethinking global health: A binding convention for R&amp;D for
            pharmaceutical products.</article-title>
          <comment>Research Note 42. Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.southcentre.org/index.php?option=com_content&amp;view=article&amp;id=1651%3Arethinking-global-health-a-binding-convention-for-rad-for-pharmaceutical-products&amp;Itemid=335&amp;lang=en"
              xlink:type="simple"
              >http://www.southcentre.org/index.php?option=com_content&amp;view=article&amp;id=1651%3Arethinking-global-health-a-binding-convention-for-rad-for-pharmaceutical-products&amp;Itemid=335&amp;lang=en</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-World7">
        <label>64</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Organization</collab>
          <year>2006</year>
          <article-title>Constitution of the World Health Organization. Basic Documents, Forty-fifth
            edition, Supplement, October 2006.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.who.int/governance/eb/who_constitution_en.pdf"
              xlink:type="simple"
              >http://www.who.int/governance/eb/who_constitution_en.pdf</ext-link>. Accessed 11
            April 2012</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Hein1">
        <label>65</label>
        <element-citation publication-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hein</surname>
              <given-names>W</given-names>
            </name>
            <name name-style="western">
              <surname>Moon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <year>Forthcoming</year>
          <source>Informal norms in global governance: Negotiating global intellectual property
            rules, human rights, and access to medicines</source>
          <publisher-loc>Aldershot</publisher-loc>
          <publisher-name>Ashgate</publisher-name>
          <comment>In press</comment>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Nikogosian1">
        <label>66</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Nikogosian</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <year>2010</year>
          <article-title>WHO framework convention on tobacco control: A key
            milestone.</article-title>
          <source>Bull World Health Organ</source>
          <volume>88</volume>
          <issue>2</issue>
          <fpage>83</fpage>
          <pub-id pub-id-type="pmid">20428359</pub-id>
        </element-citation>
      </ref>
      <ref id="pmed.1001218-Pharmaceutical1">
        <label>67</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Pharmaceutical Research and Manufacturers of America
            (PhRMA)</collab>
          <year>2011</year>
          <article-title>Pharmaceutical industry profile 2011.</article-title>
          <comment>Available: <ext-link ext-link-type="uri"
              xlink:href="http://www.phrma.org/sites/default/files/159/phrma_profile_2011_final.pdf"
              xlink:type="simple"
              >http://www.phrma.org/sites/default/files/159/phrma_profile_2011_final.pdf</ext-link>.
            Accessed 11 April 2012</comment>
        </element-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ARV</term>
          <def>
            <p>antiretroviral</p>
          </def>
        </def-item>
        <def-item>
          <term>CEWG</term>
          <def>
            <p>WHO Consultative Expert Working Group on R&amp;D: Financing and Coordination</p>
          </def>
        </def-item>
        <def-item>
          <term>DNDi</term>
          <def>
            <p>Drugs for Neglected Diseases initiative</p>
          </def>
        </def-item>
        <def-item>
          <term>LMIC</term>
          <def>
            <p>low- and middle-income country</p>
          </def>
        </def-item>
        <def-item>
          <term>MMV</term>
          <def>
            <p>Medicines for Malaria Venture</p>
          </def>
        </def-item>
        <def-item>
          <term>PDP</term>
          <def>
            <p>product development partnership</p>
          </def>
        </def-item>
        <def-item>
          <term>R&amp;D</term>
          <def>
            <p>research and development</p>
          </def>
        </def-item>
        <def-item>
          <term>TRIPS</term>
          <def>
            <p>Agreement on Trade-Related Aspects of Intellectual Property Rights</p>
          </def>
        </def-item>
        <def-item>
          <term>WHO</term>
          <def>
            <p>World Health Organization</p>
          </def>
        </def-item>
        <def-item>
          <term>WTO</term>
          <def>
            <p>World Trade Organization</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>
